Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | USP14 | P54578 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150502 | 0.90 | REN (0.50) | RENPOLBMEN1KMT2AGPR119 | |
| SCHEMBL1149614 | 0.83 | REN (0.50) | RENPOLBMEN1KMT2AGPR119 | |
| SCHEMBL1149623 | 0.83 | REN (0.70) | REN | |
| SCHEMBL1144657 | 0.80 | REN (0.48) | RENMEN1KMT2AGPR119MAPT | |
| SCHEMBL1149873 | 0.79 | REN (0.77) | REN | |
| SCHEMBL1144191 | 0.78 | CHRM2 (0.52) | RENPOLBMEN1KMT2AGPR119 | |
| SCHEMBL1149878 | 0.77 | REN (0.75) | RENMAPT | |
| SCHEMBL1149809 | 0.76 | REN (0.70) | RENPOLBGPR119 | |
| SCHEMBL1150397 | 0.76 | USP14 (0.43) | RENMEN1KMT2AUSP14SMN1; SMN2 | |
| SCHEMBL1149661 | 0.74 | REN (0.49) | RENPOLBMEN1KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580813-B2 | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2240482-B1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| EP-2240482-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009095162-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, PM20D2, CDK20 | REN 1/4885POLB 3367/4885MEN1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.